YOLFTbeta
Vir Biotechnology Inc

Vir Biotechnology Inc

VIR · NASDAQ · Healthcare / Biotechnology

9.96USD-2.16 (-17.82%)

Price History

Full chart

Market Stats

Previous Close12.12
Open10.46
Day Range9.71 – 10.70
52-Week Range5.32 – 14.38
Volume16.65M
Market Cap2.34B
P/E (TTM)0.00
Forward P/E4.27
EPS-1.18
Dividend Yield0.00%
Beta1.74
50-Day Avg11.03
200-Day Avg9.64

About

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Marianne De Backer M.B.A., M.Sc., Ph.D.
  • Employees367
  • Headquarters1800 Owens Street, San Francisco, CA, United States, 94158, USA
  • Websitehttps://www.vir.bio

Leadership

  • Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.President, CEO & Director · b. 1969
  • Ms. Vanina de Verneuil J.D.Executive VP, General Counsel & Corporate Secretary · b. 1979
  • Dr. Lawrence Corey M.D.Co-Founder & Scientific Advisor · b. 1947
  • Dr. Louis J. Picker M.D.Co-Founder & Scientific Advisor
  • Mr. Aziz Sawaf C.F.A., M.B.A.Executive VP, CFO & Principal Financial Officer · b. 1982
  • Mr. Brent Sabatini CPA, M.B.A.Senior VP, Principal Accounting Officer & Chief Accounting Officer · b. 1974
  • Dr. Maninder Hora Ph.D.Executive VP & Chief Technical Operations Officer · b. 1954
  • Dr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific Officer
  • Dr. Kiki Patel Pharm.D.Head of Investor Relations
  • Ms. Carolyn WangSenior Vice President of Corporate Communications

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.71M10.67M711.00K76.37M1.10B1.62B86.18M74.20M68.56M
Growth (%)-+293.94%-93.34%+10640.93%+1334.39%+47.51%-94.67%-13.90%-7.61%
Cost of Revenue62.51M100.23M143.07M301.58M71.68M161.81M22.22M15.40M11.71M
Gross Profit-62.36M-99.36M711.00K76.37M1.02B1.45B63.96M58.80M56.85M
Gross Margin-2302.92%-931.39%100.00%100.00%93.46%89.99%74.22%79.24%82.92%
Operating Expense18.43M19.33M178.69M373.35M602.99M620.92M724.97M582.22M524.87M
Operating Income-80.80M-118.69M-177.98M-296.98M420.75M833.07M-661.00M-523.42M-468.02M
Operating Margin-2983.64%-1112.60%-25032.21%-388.88%38.41%51.56%-767.01%-705.37%-682.68%
EBITDA-80.36M-115.94M-173.46M514.33M432.73M848.56M-641.55M-508.86M-456.34M
EBITDA Margin-2967.69%-1086.76%-24396.91%673.49%39.50%52.52%-744.43%-685.75%-665.65%
Net Income-69.85M-115.88M-174.68M-298.67M528.58M515.84M-615.06M-521.96M-437.99M
Net Income Margin-2579.47%-1086.28%-24568.64%-391.09%48.25%31.92%-713.69%-703.40%-638.87%
R&D62.08M97.47M148.47M302.41M442.19M467.87M550.92M463.19M432.80M
R&D as % of Total Revenue2292.47%913.70%20882.14%395.99%40.37%28.96%639.27%624.20%631.30%
Interest Expense007.97M3.81M272.91M183.15M---
Interest Expense % of Total Revenue0.00%0.00%1120.53%4.99%24.91%11.33%---

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets251.57M191.60M512.07M918.76M1.95B2.80B1.92B1.40B1.00B
Total Liabilities320.48M370.77M88.13M201.91M522.42M724.13M328.82M248.43M237.55M
Total Equity-68.92M-179.18M423.94M716.85M1.43B2.08B1.59B1.15B765.28M
Cash187.92M47.60M109.33M436.57M347.81M848.63M241.58M222.95M234.11M
Total Debt-10.14M1.14M70.18M137.49M127.97M124.54M97.89M186.91M
Net Debt-187.92M-37.46M-109.10M-366.39M-210.33M-720.66M-117.04M-125.06M-47.20M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-66.38M-94.10M-129.63M-190.94M-47.59M1.66B-778.78M-446.35M-391.78M
Investing Cash Flow-29.99M-60.44M-256.16M-9.86M-140.81M-1.19B164.73M499.37M310.37M
Financing Cash Flow271.18M24.98M449.24M529.47M100.33M34.76M7.38M4.39M3.79M
Capital Expenditure2.74M8.19M8.94M6.55M21.82M68.01M21.57M7.30M4.83M
Free Cash Flow-69.12M-102.29M-138.57M-197.49M-69.41M1.60B-800.36M-453.65M-396.61M
Dividends Paid00-------
FCF to OCF104.13%108.71%106.90%103.43%145.84%95.91%102.77%101.64%101.23%
Dividend Paid to FCF0.00%0.00%-------

Earnings

Report DateSep 3, 2019Nov 19, 2019Mar 26, 2020May 12, 2020Aug 11, 2020Nov 10, 2020Feb 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Feb 24, 2022May 5, 2022Aug 9, 2022Nov 3, 2022Feb 23, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 22, 2024May 2, 2024Aug 1, 2024Oct 31, 2024Feb 20, 2025May 7, 2025Aug 6, 2025Nov 5, 2025Feb 23, 2026May 6, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate-0.71-3.33-0.67-0.56-0.62-0.60-0.70-0.11-0.400.093.043.620.46-0.31-0.39-0.86-1.19-1.19-1.01-1.05-0.89-1.08-0.89-0.84-0.72-0.70-0.540.480.83-0.80
EPS Actual-0.51-4.60-0.69-0.71-0.27-0.67-0.83-1.320.460.823.923.85-0.581.30-0.76-1.06-1.45-1.22-0.86-0.48-1.02-1.56-0.76-0.88-0.80-1.17-0.31-0.850.47-0.57
Surprise28.17%-38.14%-2.99%-26.79%56.45%-11.67%-18.57%-1100.00%215.00%811.11%28.95%6.35%-226.09%519.35%-94.87%-23.26%-21.85%-2.52%14.85%54.29%-14.61%-44.44%14.61%-4.76%-11.11%-67.14%42.59%-277.08%-43.37%28.75%
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap2.34B
Enterprise Value1.72B
Trailing P/E0.00
Forward P/E4.27
Price / Sales7.72
Price / Book2.33
EPS-1.18
Book Value5.29
Revenue (TTM)302.80M
Gross Profit (TTM)-111.02M
EBITDA-201.32M
Profit Margin-61.03%
Operating Margin55669.15%
Return on Equity-21.84%
Return on Assets-12.47%
Shares Outstanding171.27M
Shares Float141.13M
Beta1.74
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 9 analystsTarget 21.50
  • Strong Buy
    6
  • Buy
    3

Ownership Breakdown

Institutions
84.36%
Insiders
6.50%
Retail / Other
9.14%

Top Institutional Holders

  • BlackRock Inc
    20.68M12.07%
  • ARCH VENTURE CORP
    12.69M7.41%
  • Vanguard Portfolio Management, LLC
    11.50M6.71%
  • SB INVESTMENT ADVISERS (UK) LTD
    10.95M6.39%
  • State Street Corp
    9.96M5.82%
  • GSK PLC
    8.55M4.99%
  • Vanguard Capital Management, LLC
    6.39M3.73%
  • Point72 Asset Management, L.P.
    5.67M3.31%
  • Geode Capital Management, LLC
    3.35M1.96%
  • Dimensional Fund Advisors, Inc.
    3.32M1.94%
  • ADAR1 Capital Management LLC
    2.46M1.43%
  • The Goldman Sachs Group Inc
    2.37M1.38%
  • FMR Inc
    2.32M1.35%
  • Morgan Stanley - Brokerage Accounts
    2.21M1.29%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    7.63M4.45%
  • Vanguard MStar Total Stk Mkt Idx Invest
    4.87M2.84%
  • iShares Russell 2000 ETF
    3.48M2.03%
  • Vanguard Small Cap Index
    3.43M2.00%
  • State Street® SPDR® S&P® Biotech ETF
    2.73M1.60%
  • Vanguard Strategic Equity Inv
    2.14M1.25%